Skip to main content
SpringerLink
Log in

Dermatologische Tumoren

  • Chapter
PET/CT-Atlas

  • 3807 Accesses

Zusammenfassung

Die Inzidenz von Melanomen hat in den letzten Jahren deutlich zugenommen. Die Anwendung der PET/CT-Diagnostik bei diesem Krankheitsbild ist um ein Vielfaches häufiger als bei anderen dermatologischen Tumoren. Vor allem hinsichtlich neuer systemischer Therapieansätze kann die PET/CT eine wichtige Rolle für eine notwendige kritische Evaluierung des Krankheitsverlaufs bzw. Therapieansprechens spielen. Das initiale Krankheitsstadium ist dabei, wie bei den meisten Tumorerkrankungen, von entscheidender Bedeutung. Darüber hinaus bestimmen Tumorgröße/-dicke, Ulzerationen, das Vorhandensein und die Anzahl von Mikrometastasen sowie Fernmetastasen über Diagnostik und Therapie mit. Gerade die Abklärung von regionalen oder Fernmetastasen war seit Beginn der klinischen PET-Nutzung eine wichtige Indikation für die PET/CT. Zunehmend rückt auch die Diagnostik des Primärtumors mit PET/CT in den Fokus.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 299.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Literatur

  1. Belhocine T, Pierard G, De Labrassine M et al. (2002) Staging of regional nodes in AJCC stage I and II melanoma: 18FDG PET imaging versus sentinel node detection. The Oncologist 7: 271–278

    Article  PubMed  Google Scholar 

  2. Gambhir SS, Czernin J, Schwimmer J et al. (2001) A tabulated summary of the FDG PET literature. J Nucl Med 42 (suppl): 1S–93 S

    Google Scholar 

  3. Holzmann H, Altmeyer P, Hor G, Hahn K (1985) Dermatologie und Nuklearmedizin. Springer, Berlin

    Book  Google Scholar 

  4. Hor G, Maul FD, Krause BJ, Werner RJ, Baum RP, Brandhorst I, Holzmann H (1995) The skin. In: Wagner HN, Szabo Z, Buchanan JW (eds) Principles of nuclear medicine. Saunders, Philadelphia, S 1029–1033

    Google Scholar 

  5. Hor G, Werner R, Klusmann A, Baum RP, Maul BJ, Krause FD, Holzmann H (1996) Diagnostische Beitrage der Nuklearmedizin fur den Dermatologen—Eine Standortanalyse nach 15-jahriger Kooperation. H + G 71: 594–610

    Google Scholar 

  6. Iagaru A, Quon A, Johnson D et al. (2007) 2-deoxy-2-[F-18]fluoro- D-glucose positron positron emission tomography/computed tomography in the management of melanoma. Mol Imaging Biol 9: 50–57

    Article  CAS  PubMed  Google Scholar 

  7. Vidal-Sicart S, Pons F, Fuertes S et al. (2004) Is the identification of in-transit sentinel lymphnodes in malignant melanoma patients really necessary? Eur J Nucl Med Mol Imag 31: 945–949

    Article  Google Scholar 

  8. Lee CC, Faries MB, Wanek LA, Morton DL (2009) Improved survival for stage IV melanoma from an unknown primary site. J Clin Oncol 27(21): 3489–3495

    Article  PubMed  PubMed Central  Google Scholar 

  9. Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (2013) Krebs in Deutschland 2009/2010. Beitrage zur Gesundheitsberichterstattung des Bundes. Ausgabe, Berlin, 60–63. http://www.rki.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2013/krebs_ in_deutschland_2013.pdf;jsessionid = 8D65E3DB2765A1D4C6CE- 39F27AB011D8.2_cid372?__blob = publicationFile. (Zugriff: 18.03.2015)

  10. S3 Leitlinie Melanom – 032-024l_S3_Melanom_Diagnostik_Therapie_ Nachsorge_2013-02.pdf. http://www.awmf.org/uploads/tx_szleitlinien/032-024l_S3_Melanom_Diagnostik_Therapie_ Nachsorge_2013-02.pdf

  11. Rinne D, Baum RP, Hor G, Kaufmann R (1998) Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 82(9): 1664–1671

    Article  CAS  PubMed  Google Scholar 

  12. Reinhardt MJ, Joe AY, Jaeger U et al. (2006) Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 24(7): 1178–1187

    Article  PubMed  Google Scholar 

  13. Rodriguez Rivera AM, Alabbas H, Ramjaun A, Meguerditchian AN (2014) Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis. Surg Oncol 23(1):11–16. doi:10.1016/j.suronc.2014.01.002

    Article  PubMed  Google Scholar 

  14. Pfluger T, Melzer HI, Schneider V et al. (2011) PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT. Eur J Nucl Med Mol Imaging 38(5): 822–831. doi:10.1007/s00259-010-1702-z

    Article  PubMed  Google Scholar 

  15. Bronstein Y, Ng CS, Rohren E et al. (2012) PET/CT in the management of patients with stage IIIC and IV metastatic melanoma considered candidates for surgery: evaluation of the additive value after conventional imaging. Am J Roentgenol 198(4): 902–908. doi:10.2214/AJR.11.7280

    Article  Google Scholar 

  16. Jouvet JC, Thomas L, Thomson V et al. (2014) Whole-body MRI with diffusion-weighted sequences compared with 18 FDG PET-CT, CT and superficial lymph node ultrasonography in the staging of advanced cutaneous melanoma: a prospective study. J Eur Acad Dermatol Venereol 28(2): 176–185

    Article  CAS  PubMed  Google Scholar 

  17. Xing Y, Bronstein Y, Ross MI et al. (2011) Contemporary Diagnostic Imaging Modalities for the Staging and Surveillance of Melanoma Patients: a Meta-analysis. J Natl Cancer Inst 103(2): 129–142. doi:10.1093/jnci/djq455

    Article  PubMed  PubMed Central  Google Scholar 

  18. Wagner T, Chevreau C, Meyer N, Mourey L, Courbon F, Zerdoud S (2012) Routine FDG PET-CT in patients with a high-risk localized melanoma has a high predictive positive value for nodal disease and high negative predictive value for the presence of distant metastases. J Eur Acad Dermatol Venereol 26(11): 1431–1435. doi:10.1111/j.1468–3083.2011.04312.x

    Article  CAS  PubMed  Google Scholar 

  19. Etchebehere ECSC, Romanato JS, Santos AO, Buzaid AC, Camargo EE (2010) Impact of [F-18] FDG-PET/CT in the restaging and management of patients with malignant melanoma. Nucl Med Commun 31(11): 925–930. doi:10.1097/MNM.0b013e32833f6137

    Article  PubMed  Google Scholar 

  20. Danielsen M, Hojgaard L, Kjar A, Fischer BM (2013) Positron emission tomography in the follow-up of cutaneous malignant melanoma patients: a systematic review. Am J Nucl Med Mol Imaging 4(1): 17–28

    PubMed  PubMed Central  Google Scholar 

  21. Beasley GM, Parsons C, Broadwater G et al. (2012) A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma. Ann Surg 256(2): 350–356. doi:10.1097/SLA.0b013e318256d1f5

    Article  PubMed  PubMed Central  Google Scholar 

  22. Sanghera B, Wong WL, Sonoda LI et al. (2014) FLT PET-CT in evaluation of treatment response. Indian J Nucl Med 29(2): 65–73

    Google Scholar 

  23. Aarntzen EHJG, Srinivas M, De Wilt JHW et al. (2011) Early identification of antigen-specific immune responses in vivo by [18F]- labeled 3’-fluoro-3’-deoxy-thymidine ([18F]FLT) PET imaging. Proc Natl Acad Sci U S A 108(45): 18396–18399. doi: 10.1073/pnas.1113045108

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Baudy AR, Dogan T, Flores-Mercado JE et al. (2012) FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973. EJNMMI Res 2(1): 22. doi:10.1186/2191-219X-2-22

    Article  PubMed  PubMed Central  Google Scholar 

  25. Beaino W, Anderson CJ (2014) PET imaging of very late antigen-4 in melanoma: comparison of 68 Ga- and 64Cu-labeled NODAGA and CB-TE1A1P-LLP2A conjugates. J Nucl Med 55(11): 1856–1863

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Qin C, Liu H, Chen K et al. (2014) Theranostics of Malignant Melanoma with 64CuCl2. J Nucl Med 55(5): 812–817. doi: 10.2967/jnumed.113.133850

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Diagnostisch Therapeutisches Zentrum, Kadiner Straße 23, 10243, Berlin

    Prof. Dr. med. Wolfgang Mohnike

  2. Kuckucksweg 25, 61462, Königstein/Taunus

    Prof. Dr. med. Gustav Hör

  3. Klinik für Diagnostische und Therapeutische, Nuklearmedizin, Klinikum Fulda gAG, Pacelliallee 4, 36043, Fulda

    Dr. med. Andreas Hertel

Authors
  1. Prof. Dr. med. Wolfgang Mohnike
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Gustav Hör
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dr. med. Andreas Hertel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Diagnostisch Therapeutisches Zentrum, Berlin, Deutschland

    Wolfgang Mohnike

  2. Königstein, Deutschland

    Gustav Hör

  3. Klinikum für Nuklearmedizin, Klinikum Fulda, Fulda, Deutschland

    Andreas Hertel

  4. UCLA Molecular & Medical Pharmacology, Los Angeles, CA, USA

    Heinrich Schelbert

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Mohnike, W., Hör, G., Hertel, A. (2016). Dermatologische Tumoren. In: Mohnike, W., Hör, G., Hertel, A., Schelbert, H. (eds) PET/CT-Atlas. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-48842-3_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-48842-3_10

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-48841-6

  • Online ISBN: 978-3-662-48842-3

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation